Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00305110 · ClinicalTrials.gov registry record · Phase 2
Safety of Hydromorphone in Adult Patients Presenting to the Emergency Department With Acute Severe Pain
A Phase 2 study of Acute Pain, sponsored by Montefiore Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 298
- Enrollment target
- 1
- Study location
NCT00305110: Completed Phase 2 study of Acute Pain, sponsored by Montefiore Medical Center.
NCT00305110 is a Phase 2 study of Acute Pain that has completed, run by Montefiore Medical Center. The registered enrollment target is 298 participants, above the 262-participant average among 50 other Acute Pain trials with a reported enrollment target (14% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00305110, a Phase 2 study of Acute Pain, has completed, sponsored by Montefiore Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 298 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the safety and speed of onset of 2mg intravenous hydromorphone (Dilaudid) in patients weighing at least 150 lbs presenting to the emergency department with acute severe pain
Primary Outcome
Naloxone is a reversal agent - a medication that reverses the effects of another. Hydromorphone is an opiate pain medication that acts as a depressant to the body, thereby slowing it down. A large slow down is dangerous, as it can cause the breathing rate to slow down too much and prevent enough oxygen from entering the body and reaching the brain, resulting in death. Naloxone is a medication that blocks the receptors binding opiate pain medication and reversing the body's reaction to the hydrom
Conditions Studied
Interventions
- DRUG 2 mg IV hydromorphone
Study Locations (1)
New York
- Montefiore Medical Center - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 298 participants |
| Start Date | 2006-01 |
| Est. Completion | 2006-10 |
| Phase | Phase 2 |
What the finished NCT00305110 record still lists
NCT00305110 is an interventional study that assigns participants to a tested intervention. The registered 298 participants enrollment target is mid-sized for trials with a published cap, above the 262-participant average among 50 other Acute Pain trials with a reported enrollment target (14% higher).
The record links to 1 condition, with Acute Pain appearing as the primary indexed condition, and to 1 intervention - of which 2 mg IV hydromorphone is the first listed.
NCT00305110 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00305110 about?
NCT00305110 is a clinical study titled "Safety of Hydromorphone in Adult Patients Presenting to the Emergency Department With Acute Severe Pain". The purpose of this study is to determine the safety and speed of onset of 2mg intravenous hydromorphone (Dilaudid) in patients weighing at least 150 lbs presenting to the emergency department with acute severe pain
What is the current status of trial NCT00305110?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 298 participants. The study started on 2006-01. Estimated completion is 2006-10.
What conditions does trial NCT00305110 study?
This clinical trial studies the following conditions: Acute Pain.
What interventions are being tested in trial NCT00305110?
The interventions under investigation include: 2 mg IV hydromorphone (DRUG).
Who is sponsoring clinical trial NCT00305110?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00305110 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00305110's enrollment target sits among peer trials
298 11th of 50 higher than 40 of 50 other Acute Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reducing Pain From Wisdom Molar Extractions
RECRUITING · Phase 2
-
Twin Block, Pain Medications and Third Molar Extractions
RECRUITING · Phase 2
-
Study of Wafermine™ for Post-bunionectomy or Abdominoplasty Pain
COMPLETED · Phase 2
-
Liposome Bupivacaine Interscalene Total Shoulder
COMPLETED · Phase 2
-
Acetaminophen Versus IV Hydromorphone for Pain in the Elderly in the ED
COMPLETED · Phase 2
-
Assessment of PF614 Effects on Experimental Pain in the Cold Pressure Test (PF614-201)
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06305624 · 298 participants · NA
Implementation of Mobile-based Programs for Alcohol Cessation in Treatment of Alcohol-associated Liver Disease
- NCT06754215 · 298 participants · NA
Smoking Cessation Intervention Development for Homeless Youth
- NCT06780111 · 298 participants · Phase 1
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
- NCT07209358 · 298 participants · NA
EDX110 Randomized Control Trial for Treatment of DFUs
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia